Assocham's first lady chief talks of the need to unleash new ideas and wonders why, when India has such politically powerful women, they're hardly to be seen in business.
Glenmark plans to start selling its anti-diarrhoea drug, Crofelemer, by the first-half of 2010 across the globe, except in North America, Europe, Japan and China, the company said. The confidence to sell the drug ahead of its rivals comes as the Crofelemer's original developer, Napo Pharmaceutical Inc, recently entered into a tie-up with a US-based drug maker, Salyx, for selling the drug in the US market, paving the way for Glenmark to sell it in the rest of the world.
In May last year, Peninsula forayed into the hospitality sector with a joint venture with textile maker and real estate developer, Arrow Webtex. The JV planned to build hotels in Mumbai, Pune, Nagpur, Nasik and Kolhapur in Maharashtra. There were also plans to develop hotels in Ahmedabad, Surat, Jamnagar, Mundra port, Goa and Kerala.
Pharma majors are collaborating with foreign companies to develop newer drugs.
Two years after India entered the product patents regime, the year 2007 saw Indian drug firms striving to shed the copycat image and become innovators with emphasis on research activities even as they resisted moves to include more medicines under price control.
According to analysts, Indian drug makers are forging alliances with overseas companies such as CD Pharma, Gnosis SpA, Crawford Healthcare and Syrio Pharma to sell drugs for chronic and acute cases. According to analysts, Indian drug makers are forging alliances with overseas companies such as CD Pharma, Gnosis SpA, Crawford Healthcare and Syrio Pharma to sell drugs for chronic and acute cases.
The less-than-anticipated results of a few big-ticket acquisitions made in the previous year earlier also acted as a dampener. Piramal Healthcare, Biocon and other drug makers spent about Rs 1,800 crore (Rs 18 billion) in 2008 for acquiring assets abroad, compared to more than Rs 5,500 crore (Rs 55 billion) spent in 2007 in 14 such major deals, according to Business Standard data.
Ranbaxy Laboratories, Dr Reddy's, Nicholas Piramal and three other Indian drug companies cut their research costs by separating the units involved in developing new drugs, thereby addressing investor concerns on low operating margins.
Dr Reddy's Laboratories & Strides Arcolabs are at a risk of raiders as their promoter holdings are less than 26%. Promoters of Dr Reddy's have 25.15% stake as on Dec 31, 2007 and the share value of the company has dipped 19.9 per cent since January 1 this year. The Bangalore-based Strides Arcolab had only 18.82% promoter-holding as on Dec 31, 2007. The stock price of the company has gone down 34% in the same period. The promoters are taking steps to correct the situation.
Retail sales of Ranbaxy Laboratories, Cipla, Nicholas Piramal, Lupin and other drug makers have jumped by over 10 per cent in the domestic market despite the sales of generics or copycat versions of patented drugs falling in leading global markets such as the US and Europe.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Which of these celebrity brides looked best in their red bridal look. Take the poll now.
Partnership between Israel and India is doing wonders, the visiting prime minister tells business leaders.
Over 30 domestic pharmaceutical companies, including Ranbaxy, Cipla, Nicholas Piramal, Zydus Cadila and Torrent, face a possible ban on the sale of the generic version of Merck's pain management drug in the Indian market.
Ahmedabad-based firm to fund deal through equal amount of equity and debt.
Indiabulls Wholesale Services, the retail arm of Indiabulls Real Estate, has acquired Piramyd Retail, a company owned by the Ashok Piramal Group which runs 35 neighbourhood retail stores and seven lifestyle stores. Indiabulls Wholesale has acquired 63.92 per cent stake in Piramyd Retail at an enterprise value of around Rs 208 crore (Rs 2.08 billion), said sources close to the deal.
Piramyd Retail, a part of the Ashok Piramal group, will launch a new branding strategy for its departmental store format, Piramyd Megastore, in a month's time.
The company is demerging its new chemical entity research unit into a separate company to meet the demands of increased spend on research and development, and to insulate investors from the risks involved. According to the deal signed with Merck, NPIL will discover and develop new drugs for two selected targets provided by Merck in the area of cancer.
A camera when held in the right hands becomes a sponge that absorbs life, its colours, emotions and mood swings in totality. This is where ace photographer Fawzan Husain and his work fall into context.
.jpg)
The Companies Bill asked for promoting gender diversity by specifying induction of a minimum number of women directors
The multi-crore brands were being marketed and sold by Boots Piramal Joint Venture till September.
Ashok Piramal Group company Peninsula Land has inked a property deal worth Rs 1,200 crore (Rs 12 billion) with Essar Realty Holdings, the realty arm of the Essar Group, to sell and lease premises at its upcoming IT park named Peninsula Technopark on LBS Marg in Kurla. The deal was signed recently, according to sources.
Domestic pharma firm inks first-of-its-kind pact.
Asian Paints, Cipla, Bharat Forge, Dabur India, Nicholas Piramal and Satyam Computer Services are among the 20 Indian corporate entities that have found place in Forbes' list of 'Best Small Asian Companies'.
A quiz on women who have made it big in the corporate world.
Giving another boost to the great Indian growth story, seven domestic firms have been named as the emerging global challengers to the world's leading blue chips by the global equity research major Standard and Poor's.
Instead of the minority stake they held earlier, now they have controlling stake in many firms
In a letter to the Business School community on Wednesday, Nohria said he will step down from the position of dean of the Harvard Business School (HBS) on June 30, 2020, after a decade in the role.
'Sonam is my lucky charm.' 'Because of her, 2018 went well for me, as I got four big weddings.' 'It started with Sonam's in November, then Deepika Padukone-Ranveer Singh's in December, Kapil Sharma's wedding and then Isha Ambani's wedding.'
The Indian majors had a last minute meeting with civil aviation ministry officials before filing their bids.
Foreign players seeking to participate in the modernisation of Delhi and Mumbai airports, in consortium with Indian partners, have strongly reacted to the terms of the tender, which would be open for bidding from Wednesday. \n
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances